PubMed Health⌕ Search

Biomedical subjects

J G Hansen

Publications and source records attributed to J G Hansen.

43 records · Page 3Linked to original sources

Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.

Incorporation of the serine protease active site reagent diisopropyl fluorophosphate (DFP) into a plasminogen activator with an Mr of approximately 52000 released from cultured human glioblastoma cells was strongly enhanced by incubation with plasmin. This observation led to the isolation of an inactive form of the enzyme from serum-free conditioned culture fluid by affinity chromatography on a column of a Sepharose-bound monoclonal antibody raised against urokinase. An 831-fold purification was obtained with a yield of 41%. The purified molecule was homogeneous as evaluated by polyacrylamide gel electrophoresis with sodium dodecyl sulfate (NaDodSO4), having one stainable band under nonreducing as well as reducing conditions with an Mr of approximately 52000. It was unable to activate plasminogen, but catalytic amounts of plasmin converted it into active enzyme. After NaDodSO4-polyacrylamide gel electrophoresis, the active enzyme showed one band under nonreducing conditions, but after reduction, two bands with Mr values of approximately 20000 and 32000 were observed. The active enzyme incorporated [3H]DFP into the approximately Mr 32000 band, while no incorporation was observed into the inactive form. These findings show that the Mr 52000 human plasminogen activator exists in a proenzyme form consisting of a single polypeptide chain that by proteolysis between half-cystine residues is converted into the active enzyme consisting of two chains with molecular weights of approximately 20000 and 32000, the active site being on the latter chain. The results are consistent with the active form of the enzyme being identical with the higher molecular weight form of urokinase, and together with recent observations that a murine plasminogen activator is released from sarcoma virus transformed cells as an inactive proenzyme, they suggest that zymogens to plasminogen activators are of more general occurrence.

Antibodies, Monoclonal↗

In vitro studies on the tumour cytotoxicity of normal, stimulated and immunologically activated mouse macrophages.

Peripheral macrophages (MO) from mice injected with proteose-peptone (P), thioglycollate (T) medium or BCG and from mice undergoing a graft versus host (GVH) reaction were tested for their cytotoxicity towards three murine tumour cell lines. The ability of lipopolysaccharide (LPS) and lymphokines to increase cytotoxicity was also studied. TMO were only slightly cytotoxic and this cytotoxicity was not enhanced by LPS and lymphokines. PMO showed the same degree of cytotoxicity as TMO, but this could be enhanced by LPS and lymphokines. Resident macrophages (RMO) sometimes resembled TMO and sometimes PMO. BCGMO were highly cytotoxic and could not be further activated by LPS and lymphokines. GVHMO were moderately cytotoxic but could not be further activated by LPS and lymphokines in contrast to the MO from hybrid controls.

Animals↗